Agilent Wants Justices To Eye Invalidation Of CRISPR Patents
Agilent Technologies wants the U.S. Supreme Court to take up its challenge to a Federal Circuit finding that claims in a pair of its patents on the gene-editing tool CRISPR were...To view the full article, register now.
Already a subscriber? Click here to view full article